UNSPSC 51111871: Vorozole

This classification denotes a non-steroidal aromatase inhibitor with the molecular formula C16H13ClN6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1E2S9YXV2A, chemically known as 6-((4-chlorophenyl)(1h-1,2,4-triazol-1-yl)methyl)-1-methyl-1h-benzotriazole,d- but generally known as vorozole, which bears US NIH Compound Identifier 60796. European Medicines Agency schedules Vorozole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00088MIG.

UNSPSC 51111871 Vorozole, a Commodity code, encompasses generic pharmaceutical products supplied through state and local cooperative purchasing vehicles to government health-care and social-services facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, recently issued an RFP in January 2026 to establish multi-award contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota and Oregon. The scope centers on manufacturers supplying finished pharmaceutical products with specific National Drug Codes (NDCs), requiring detailed product information, manufacturing certifications, and compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA). Vendors must maintain contractual relationships with at least two of three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and demonstrate pricing flexibility through formats including flat price, net price variants, or WAC-minus structures. Issuing bodies under this code consist of state purchasing offices coordinating cooperative agreements that serve multi-state and multi-local jurisdictions rather than individual counties or cities acting independently.

Recent activity centers on the upper Midwest, with MMCAP's RFP posted January 20, 2026 and closing March 26, 2026, reflecting a two-year initial contract term effective July 1, 2026 with optional extensions through June 30, 2028 for incumbents. Evaluation weights pricing competitiveness at 75 percent and administrative compliance at 20 percent combined, with fixed pricing, EDI capability, and the 3 percent administrative fee each carrying 5 percent weight. Vendors must carry commercial general liability of $5 million per occurrence and network security and privacy liability of $2 million, with products requiring FDA compliance, one-year minimum expiration dates from manufacture, and six-month minimum shelf life. The RFP does not disclose specific award values or set-aside restrictions; submissions are made through the ePro procurement system with pricing delivered in CSV format converted from Excel spreadsheets.